툴젠 둜고

툴젠 (199800) μ£Όκ°€ 및 μ’…λͺ© 정보

툴젠 μ‹€μ‹œκ°„ μ£Όκ°€

툴젠 ν˜„μž¬κ°€ 상세 정보
ν•­λͺ© κ°’
ν˜„μž¬κ°€ 70,500 원
λ³€λ™λŸ‰ β–Ό 3700.00 원
변동λ₯  -4.99%
κ±°λž˜λŸ‰ 54,776
κ±°λž˜λŒ€κΈˆ 3,881,903,350 원

툴젠 일별 μ£Όκ°€

툴젠의 κ³Όκ±° 일별 μ£Όκ°€
λ‚ μ§œ μ‹œκ°€ κ³ κ°€ μ €κ°€ μ’…κ°€ κ±°λž˜λŸ‰ κ±°λž˜λŒ€κΈˆ
5/5/2026 92,500 108,900 90,800 101,200 158,802 16,243,679,950
5/6/2026 104,200 118,900 100,800 118,500 108,881 12,207,689,950
5/7/2026 125,000 129,800 120,800 122,800 78,485 9,846,725,750
5/10/2026 131,400 139,500 127,500 137,000 80,575 10,856,129,400
5/11/2026 141,700 142,000 128,000 138,200 75,892 10,318,622,250
5/12/2026 134,100 137,700 122,000 130,700 41,980 5,503,407,950
5/13/2026 128,000 132,300 121,300 125,400 52,967 6,602,088,000
5/14/2026 111,000 111,700 91,200 96,600 196,492 19,726,025,350
5/17/2026 79,300 84,500 77,700 80,000 104,916 8,542,273,450
5/18/2026 79,300 79,300 68,800 74,200 148,487 10,764,435,950

툴젠 νšŒμ‚¬ 정보

μ‹œμž₯ μ‹œκ°€μ΄μ•‘ κΈ°μ—…μˆœμœ„ μ£Όμ‹μˆ˜ 외ꡭ인 비쀑 μ‚°μ—…κ΅° μ„ΈλΆ€ μ‚°μ—…κ΅° 52μ£Ό 졜고 52μ£Ό μ΅œμ €
kosdaq 6,673μ–΅ 169μœ„ 8,993,829 1.77% ν—¬μŠ€μΌ€μ–΄ 생λͺ…κ³Όν•™/곡학 142,000 26,650

툴젠 κΈ°μ—… κ°œμš”

νˆ΄μ  μ€ 1999λ…„ 10μ›” μ„€λ¦½λœ κΈ°μ—…μœΌλ‘œ μœ μ „μžκ΅μ • μ—°κ΅¬κ°œλ°œ 및 μœ μ „μžκ΅μ • ν”Œλž«νΌ 기술 기반 νŠΉν—ˆμˆ˜μ΅ν™” 사업 및 치료제/동식물 μ œν’ˆ 개발 λ“±μ˜ 사업을 μ˜μœ„ν•˜κ³  μžˆλ‹€. μ£Όμš” λ§€μΆœμ€ λΌμ΄μ„ μŠ€ μˆ˜μž…μ—μ„œ λ°œμƒν•˜κ³  μžˆλ‹€. λ‹Ήμ‚¬λŠ” ZFN, TALEN, CRISPR, Cas9κ³Ό 같은 3μ’…μ˜ μœ μ „μžκ°€μœ„λ₯Ό λͺ¨λ‘ κ°œλ°œν•œ 세계 유일의 νšŒμ‚¬μ΄λ©°, CRISPR μœ μ „μžκ°€μœ„λ₯Ό μ§„ν•΅μ„Έν¬μ—μ„œ μž‘λ™ν•˜λŠ” 것을 증λͺ…ν•œ νŠΉν—ˆλ₯Ό μ „ μ„Έκ³„μ—μ„œ κ°€μž₯ λΉ λ₯΄κ²Œ μΆœμ›ν•˜κ³  세계 졜초둜 μ‚¬μ—…ν™”ν•˜μ˜€λ‹€.

툴젠 AI예츑

AIμ˜ˆμΈ‘κΈ°λŠ” νˆ΄μ  μ„ κ°•λ ₯맀도 Β· 맀도 Β· 쀑립 Β· 맀수 Β· κ°•λ ₯맀수 둜 μ˜ˆμΈ‘ν–ˆμ–΄μš”.

멀버십 ν”Œλžœμ„ κ΅¬λ…ν•˜λ©΄ μ˜ˆμƒ μ£Όκ°€ μ‹œλ‚˜λ¦¬μ˜€μ™€ AI의 투자의견, λͺ©ν‘œΒ·μ†μ ˆκ°€, AIκ°€ μ°Έκ³ ν•œ 차트 νŒ¨ν„΄λ“€μ„ 확인할 수 μžˆμŠ΅λ‹ˆλ‹€.

툴젠 μ§€ν‘œλΆ„μ„

수읡λ₯  1μœ„ λ§€λ§€μ „λž΅μ€ νˆ΄μ  μ„ 맀수 Β· 맀도 Β· 보유 Β· 관망 μ€‘μ΄μ—μš”.

멀버십 ν”Œλžœμ„ κ΅¬λ…ν•˜λ©΄ 수읡λ₯  1μœ„ λ§€λ§€μ „λž΅μ˜ λ§€λ§€ μ‹œμ μ„ ν™•μΈν•˜κ³  λ‹€μŒ μ‹ ν˜Έλ₯Ό μ•Œλ¦ΌμœΌλ‘œ λ°›μ•„λ³Ό 수 μžˆμŠ΅λ‹ˆλ‹€.

μ΅œμ‹  툴젠 κ΄€λ ¨ λ‰΄μŠ€

κ΅­λ‚΄ λ°”μ΄μ˜€μ£Όκ°€ 18일 금리 μƒμŠΉ λ“±μ˜ μ—¬νŒŒλ‘œ 큰 폭으둜 ν•˜λ½ν–ˆλ‹€. μ£Όμ‹μ‹œμž₯ 자금이 λ°˜λ„μ²΄ λ“± 인곡지λŠ₯(AI) 산업에 λͺ°λ¦¬λ©΄μ„œ μ˜¬ν•΄ λ“€μ–΄μ„œλ§Œ 14% λ–¨μ–΄μ‘Œλ‹€.이날 ν•œκ΅­κ²½μ œμ‹ λ¬Έμ— λ”°λ₯΄λ©΄ λ°”μ΄μ˜€ μ—…μ’… μ£Όκ°€λ₯Ό μΆ”μ’…ν•˜λŠ” KRX ν—¬μŠ€μΌ€μ–΄μ§€μˆ˜λŠ” 이날 4287.49둜 4.7% κΈ‰λ½ν–ˆλ‹€. 이날 μ½”μŠ€ν”Όμ§€μˆ˜κ°€ 0.31% μƒμŠΉν•˜λ©° μ•ˆμ •μ μΈ 흐름을 λ‚˜νƒ€λ‚Έ 것과 λŒ€μ‘°μ μ΄λ‹€.μœ μ „μž ꡐ정 μ „λ¬ΈκΈ°μ—… 툴젠이 700얡원 규λͺ¨μ˜ μœ μƒμ¦μžμ— λ‚˜μ„ λ‹€κ³  밝힌 λ’€ 이날 17.2% κΈ‰λ½ν–ˆλ‹€. 항체약물접합체(ADC) ν”Œλž«νΌ 기업인 λ¦¬κ°€μΌλ°”μ΄μ˜€(-15.36%), 경ꡬ용(λ¨ΉλŠ”) λΉ„λ§Œμ•½μ„ κ°œλ°œν•˜λŠ” λ””μ•€λ””νŒŒλ§ˆν…(-9.7%) λ“±μ˜ 낙폭이 μ»Έλ‹€. λŒ€μž₯주인 μ‚Όμ„±λ°”μ΄μ˜€λ‘œμ§μŠ€μ™€ μ…€νŠΈλ¦¬μ˜¨, μ•Œν…Œμ˜€μ  λ„ 2~3%λŒ€ ν•˜λ½λ₯ μ„ λ‚˜νƒ€λƒˆλ‹€.κ·Έκ°„ λŒ€ν˜• λ°˜λ„μ²΄μ£Όμ— μ§‘μ€‘λλ˜ μ¦μ‹œ 자금의 쏠림도 λ°”μ΄μ˜€μ£Ό λΆ€μ§„ μš”μΈμœΌλ‘œ κΌ½νžŒλ‹€. KRX ν—¬μŠ€μΌ€μ–΄μ§€μˆ˜λŠ” μ—°μ΄ˆ λŒ€λΉ„ 13.9% ν•˜λ½ν–ˆλ‹€. μ‚Όμ„±μ „μžμ™€ SKν•˜μ΄λ‹‰μŠ€ λ“± AI λ°˜λ„μ²΄μ£Όκ°€ 이끈 μ½”μŠ€ν”Όμ§€μˆ˜(74.4% μƒμŠΉ)와 격차가 계속 λ²Œμ–΄μ§€κ³  μžˆλ‹€. λΉ„λ§Œμ•½μœΌλ‘œ κΈ°λŒ€λ₯Ό λͺ¨μ•˜λ˜ λ””μ•€λ””νŒŒλ§ˆν…κ³Ό μ§€νˆ¬μ§€λ°”μ΄μ˜€λŠ” 각각 1λ…„ μ΅œκ³ κ°€ λŒ€λΉ„ 81.9%, 74.7% ν•˜λ½, 낙폭이 λ‘λ“œλŸ¬μ‘Œλ‹€.μ‹œμž₯

툴젠이 μ•½ 700얡원 규λͺ¨μ˜ μ£Όμ£Όλ°°μ • ν›„ μ‹€κΆŒμ£Ό 일반곡λͺ¨ 방식 μœ μƒμ¦μžλ₯Ό κ²°μ •ν–ˆλ‹€κ³  15일 λ°ν˜”λ‹€. νšŒμ‚¬λŠ” 이번 증자둜 ν™•λ³΄ν•œ μžκΈˆμ„ CRISPR-Cas9 κ΄€λ ¨ κΈ€λ‘œλ²Œ νŠΉν—ˆ λΆ„μŸ λŒ€μ‘κ³Ό μ—°κ΅¬κ°œλ°œ(R&D)에 νˆ¬μž…ν•  κ³„νšμ΄λ‹€. λΈŒλ‘œλ“œμ—°κ΅¬μ†Œμ™€ μ§„ν–‰ 쀑인 저촉심사 λŒ€μ‘, λ²„ν…μŠ€μ™€ 둠자 등을 μƒλŒ€λ‘œ ν•œ 미ꡭ·유럽 νŠΉν—ˆ μΉ¨ν•΄ μ†Œμ†‘ λΉ„μš©, 치료제 μ—°κ΅¬μ†Œ 및 μ’…μžμ‚¬μ—…λ³ΈλΆ€μ˜ μ°¨μ„ΈλŒ€ νŒŒμ΄ν”„λΌμΈ μ—°κ΅¬κ°œλ°œ, κΈ€λ‘œλ²Œ 사업 운영 자금 등에 μ‚¬μš©ν•  예

이번 μ£Ό μ½”μŠ€λ‹₯ μ‹œμž₯μ—μ„œλŠ” νˆ¬μžκ²½κ³ μ’…λͺ©κ³Ό 곡맀도 κ³Όμ—΄μ’…λͺ© μ§€μ • λ“± ν•œκ΅­κ±°λž˜μ†Œμ˜ μ‹œμž₯κ²½λ³΄μ œλ„κ°€ 집쀑 가동됐닀. 9일 ν•œκ΅­...

[μΈν¬μŠ€νƒλ°μΌλ¦¬=μœ€μ„œμ—° 기자]β–Άλ§ˆκ°μ²΄ν¬β–  μ½”μŠ€ν”Όμ§€μˆ˜μ½”μŠ€ν”Όμ§€μˆ˜λŠ” 6.45% μƒμŠΉν•œ 7384.56에 λ§ˆκ°ν–ˆλ‹€.μ§€λ‚œλ°€ λ‰΄μš•μ¦μ‹œκ°€ λ―Έ-μ΄λž€ νœ΄μ „ μœ μ§€ 및 κΈ°μ—… 싀적 호쑰, λ°˜λ„μ²΄μ£Ό κ°•μ„Έ 등에 μƒμŠΉ, 유럽 μ£Όμš”κ΅­ μ¦μ‹œλŠ” 혼쑰 λ§ˆκ°ν–ˆλ‹€.이날 μ½”μŠ€ν”Όμ§€μˆ˜λŠ” 7093.01둜 κΈ‰λ“± μΆœλ°œν–ˆλ‹€. μ‹œκ°€λ₯Ό μ €μ μœΌλ‘œ μž₯ μ΄ˆλ°˜λΆ€ν„° μƒμŠΉν­μ„ ν‚€μ› κ³ , μ˜€ν›„ λ“€μ–΄ 7426.60μ—μ„œ μž₯쀑 고점을 ν˜•μ„±ν–ˆλ‹€. μ˜€ν›„ ν•œλ•Œ 7366μ„ κΉŒμ§€ μƒμŠΉν­μ„ λ°˜λ‚©ν•˜κΈ°λ„ ν–ˆμœΌλ‚˜ 재차 μƒμŠΉν­μ„ ν‚€μ› κ³ , κ²°κ΅­ 7384.56μ—μ„œ 거래λ₯Ό λ§ˆκ°ν–ˆλ‹€.외ꡭ인 λŒ€κ·œλͺ¨ 순맀수, μ‚Όμ„±μ „μž(+14.41%),

λ―Έκ΅­ μ‹ν’ˆμ˜μ•½κ΅­(FDA)이 μ΄ˆν¬κ·€ μ§ˆν™˜ ν™˜μžλ₯Ό μœ„ν•œ λ§žμΆ€ν˜• μœ μ „μž 치료제 μ•ˆμ „μ„± κ°€μ΄λ“œλΌμΈ μ΄ˆμ•ˆμ„ κ³΅κ°œν–ˆλ‹€. μœ μ „μž νŽΈμ§‘ κ³Όμ •μ—μ„œ λ°œμƒν•˜λŠ” λΉ„μ˜λ„μ  μ ˆλ‹¨(μ˜€ν”„νƒ€κΉƒ) μœ„ν—˜μ— λŒ€ν•œ ν‘œμ€€ 평가 기쀀이 λ§ˆλ ¨λ˜λ©΄μ„œ κ΄€λ ¨ 규제둜 μΈν•œ λΆˆν™•μ‹€μ„±μ΄ 쀄어듀 전망이닀. 이에 따라 κ΅­λ‚΄ μœ κ΄€ κΈ°μ—…λ“€μ˜ κΈ€λ‘œλ²Œ μ‹œμž₯ μ§„μΆœμ—λ„ 속도가 뢙을 κ²ƒμœΌλ‘œ μ˜ˆμƒλœλ‹€. 16일 업계에 λ”°λ₯΄λ©΄ 졜근 FDA μ‚°ν•˜ μƒλ¬Όν•™μ μ œμ œ 평가연ꡬ센터(CBER)κ°€ λ°œν‘œν•œ 이번

툴젠 맀좜 정보

툴젠 μ—°κ°„ 맀좜 정보

λ‚ μ§œ λ§€μΆœμ•‘ λ§€μΆœμ•‘ μ¦κ°€μœ¨ μ˜μ—…μ΄μ΅ μ˜μ—…μ΄μ΅ μ¦κ°€μœ¨ 순이읡 순이읡 μ¦κ°€μœ¨
2025.4Q 1,306,445,108 46.63% -23,294,295,129 -6.86% -36,764,280,220 -689.94%
2024.4Q 890,961,033 -19.25% -21,798,459,510 -27.57% 6,231,842,138 114.72%
2023.4Q 1,103,409,421 48.41% -17,087,547,698 11.85% -42,340,173,030 -132.93%
2022.4Q 743,463,600 - -19,385,620,000 - -18,177,155,000 -

툴젠 λΆ„κΈ° 맀좜 정보

λ‚ μ§œ λ§€μΆœμ•‘ λ§€μΆœμ•‘ μ¦κ°€μœ¨ μ˜μ—…μ΄μ΅ μ˜μ—…μ΄μ΅ μ¦κ°€μœ¨ 순이읡 순이읡 μ¦κ°€μœ¨
2026.1Q 390,709,250 -3.33% -4,593,054,586 33.81% -4,412,584,415 80.37%
2025.4Q 404,165,188 -35.90% -6,939,160,132 -28.18% -22,481,098,246 -312.74%
2025.3Q 630,536,038 342.14% -5,413,439,105 14.50% -5,446,736,915 -23.98%
2025.2Q 142,609,857 10.44% -6,331,605,117 -37.34% -4,393,164,355 1.13%

μˆœλ§€μˆ˜λŸ‰

개인: -18,642

κΈ°κ΄€: -935

외인: 36,999

λˆ„μ  μˆœλ§€μˆ˜λŸ‰

개인: -62,658

κΈ°κ΄€: -15,110

외인: 151,656

순맀수

λ‚ μ§œ 개인 κΈ°κ΄€ 외인
2026-05-19 -18,642 -935 36,999
2026-05-18 -21,747 1,839 20,205
2026-05-15 -10,367 -6,966 17,666
2026-05-14 -1,646 -691 2,421
2026-05-13 566 -720 -1,084
2026-05-12 -684 2,235 -4,617
2026-05-11 -8,535 7,408 997
2026-05-08 1,537 721 -2,646
2026-05-07 -3,975 -5,107 8,590
2026-05-06 6,856 4,168 34,546
2026-05-04 -96 -198 -555
2026-04-30 -1,822 9 -147
2026-04-29 18,167 -369 -18,605
2026-04-28 -11,741 372 11,479
2026-04-27 7,309 3 -6,824
2026-04-24 323 -22 -876
2026-04-23 -6,715 22 6,514
2026-04-22 15,485 -241 -14,387
2026-04-21 17,422 234 1,800
2026-04-20 -8,219 -85 8,505
2026-04-17 3,513 -269 -3,291

λˆ„μ  순맀수

λ‚ μ§œ 개인 κΈ°κ΄€ 외인
2026-05-19 -23,011 1,408 96,690
2026-05-18 -4,369 2,343 59,691
2026-05-15 17,378 504 39,486
2026-05-14 27,745 7,470 21,820
2026-05-13 29,391 8,161 19,399
2026-05-12 28,825 8,881 20,483
2026-05-11 29,509 6,646 25,100
2026-05-08 38,044 -762 24,103
2026-05-07 36,507 -1,483 26,749
2026-05-06 40,482 3,624 18,159
2026-05-04 33,626 -544 -16,387
2026-04-30 33,722 -346 -15,832
2026-04-29 35,544 -355 -15,685
2026-04-28 17,377 14 2,920
2026-04-27 29,118 -358 -8,559
2026-04-24 21,809 -361 -1,735
2026-04-23 21,486 -339 -859
2026-04-22 28,201 -361 -7,373
2026-04-21 12,716 -120 7,014
2026-04-20 -4,706 -354 5,214
2026-04-17 3,513 -269 -3,291

툴젠 μžμ‚° λΉ„μœ¨

μžμ‚°μ΄κ³„ λΆ€μ±„λΉ„μœ¨ μžλ³ΈλΉ„μœ¨
57,283,801,508 7.18% 92.82%

툴젠 맀좜 ꡬ성

ꡬ성 μš”μ†Œ λΉ„μœ¨
License μˆ˜μž… [νŠΉν—ˆμˆ˜μ΅ν™” 사업] 91.2%
μœ μ „μžκ°€μœ„ κ΄€λ ¨ μ œν’ˆ [기타] 3.94%
NGS 및 μ’…μžλΆ„μ„ μ„œλΉ„μŠ€ [기타] 3.84%
μƒν’ˆ, μ—°κ΅¬μš©μ—­ λ“± [기타] 1.02%

툴젠 곡맀도 ν˜„ν™©

졜근 곡맀도 κ±°λž˜λŸ‰: 2,189 (0.93%)

졜근 곡맀도 μž”κ³ : 9,888 (0.11%)

곡맀도 κ±°λž˜λŸ‰

λ‚ μ§œ μ’…κ°€ κ³΅λ§€λ„λŸ‰ 곡맀도비쀑
2026-05-19 74,200 2,189 0.93%
2026-05-18 80,000 1,166 0.67%
2026-05-15 96,600 2 0.00%
2026-05-14 125,400 4,569 5.81%
2026-05-13 130,700 4,607 6.87%
2026-05-12 138,200 5,106 4.22%
2026-05-11 137,000 4,284 3.42%
2026-05-08 122,800 3,781 3.12%
2026-05-07 118,500 5,358 2.92%
2026-05-06 101,200 2,213 0.92%
2026-05-04 92,500 1,971 1.90%
2026-04-30 83,500 2,175 2.76%
2026-04-29 89,100 1,949 3.02%
2026-04-28 94,700 1,521 1.83%
2026-04-27 90,800 2,586 3.10%
2026-04-24 96,200 4,889 3.65%
2026-04-23 90,200 2,740 3.17%
2026-04-22 93,600 2,491 1.49%
2026-04-21 99,900 8,317 7.10%
2026-04-20 97,400 2,136 2.31%
2026-04-17 93,600 2,305 2.08%

곡맀도 μž”κ³ 

λ‚ μ§œ μ’…κ°€ 곡맀도 μž”κ³  곡맀도 비쀑
2026-05-15 96,600 9,888 0.11%
2026-05-14 125,400 14,335 0.16%
2026-05-13 130,700 10,768 0.12%
2026-05-12 138,200 11,069 0.12%
2026-05-11 137,000 11,344 0.13%
2026-05-08 122,800 11,680 0.13%
2026-05-07 118,500 12,957 0.14%
2026-05-06 101,200 14,923 0.17%
2026-05-04 92,500 13,891 0.15%
2026-04-30 83,500 30,092 0.33%
2026-04-29 89,100 29,404 0.33%
2026-04-28 94,700 24,878 0.28%
2026-04-27 90,800 30,805 0.34%
2026-04-24 96,200 27,980 0.31%
2026-04-23 90,200 22,177 0.25%
2026-04-22 93,600 23,915 0.27%
2026-04-21 99,900 14,684 0.16%
2026-04-20 97,400 6,921 0.08%
2026-04-17 93,600 10,422 0.12%
2026-04-16 92,500 17,265 0.19%
2026-04-15 81,500 28,034 0.31%

툴젠 μ—…μ’… λ‚΄ 비ꡐ

생λͺ…κ³Όν•™/곡학 μ—…μ’…(89개) μ—°κ°„ κΈ°μ€€

ν•­λͺ© 툴젠 μ—…μ’… 평균 μ—…μ’… λ‚΄ μˆœμœ„
μ‹œκ°€μ΄μ•‘ 7,195.063 9,718.76 18μœ„
PER(졜근4λΆ„κΈ°) -19.047 -41.09 64μœ„
PBR 13.528 15.23 18μœ„
ROE(졜근4λΆ„κΈ°) -64.337 -45.53 68μœ„
λ°°λ‹Ήμˆ˜μ΅λ₯ (μ΅œκ·Όμ—°λ„) - - -μœ„
μ˜μ—…μ΄μ΅λ₯ (μ΅œκ·Όμ—°λ„) -1,783.029 -4,253.5 79μœ„
순이읡λ₯ (μ΅œκ·Όμ—°λ„) -2,814.07 -4,572.11 79μœ„
λΆ€μ±„λΉ„μœ¨(μ΅œκ·Όμ—°λ„) 10.391 115.25 77μœ„
λ§€μΆœμ•‘(μ΅œκ·Όμ—°λ„) 13.064 578.04 77μœ„
μ˜μ—…μ΄μ΅(μ΅œκ·Όμ—°λ„) -232.943 -49.28 74μœ„
λ‹ΉκΈ°μˆœμ΄μ΅(μ΅œκ·Όμ—°λ„) -367.643 -95.6 79μœ„